Julio C. Delgado, MD, MS

Chief of the Division of Clinical Pathology and Professor, University of Utah

Specialties

• Clinical pathology
• Immunology
• Histocompatibility

Education

• Master’s Degree—Epidemiology, Harvard School of Public Health
• Medical Degree—Universidad Industrial de Santander
• Resident—Pathology, Harvard Medical School
• Chief Resident—Pathology, Brigham and Women’s Hospital
• Fellowship—Immunogenetics, Dana-Farber Cancer Institute
• Postdoctoral Training—Immunology, CBR Institute for Biomedical Research

Certification/Affiliations

• American Board of Histocompatibility
• American Board of Pathology

Research Interests

•  Immunogenecity to monoclonal antibody therapeutics
•  Transplantation immunology

Recent Publications

• Pavlov IY, et al. Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. J Immunol Methods. 2019 Jul;470:33–9.
• Ravkov EV, et al. Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom. 2019 Jul;96(4):266–74.
• Lázár-Molnár E, Delgado JC. Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. Clin Chem. 2019 Mar;65(3): 393–405.
• Genzen JR, et al. Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice. Arch Pathol Lab Med. 2018 Apr;142(4): 507–15.